Qilian International Holding Group Limited (QLI)
- Previous Close
0.7500 - Open
0.7605 - Bid --
- Ask --
- Day's Range
0.7002 - 0.7650 - 52 Week Range
0.3550 - 1.0600 - Volume
48,003 - Avg. Volume
174,455 - Market Cap (intraday)
27.313M - Beta (5Y Monthly) 1.43
- PE Ratio (TTM)
-- - EPS (TTM)
-0.2200 - Earnings Date Apr 30, 2024 - May 4, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date Feb 27, 2023
- 1y Target Est
--
Qilian International Holding Group Limited manufactures and distributes active pharmaceutical ingredients (APIs), traditional Chinese medicine derivatives (TCMD), and other by-products in China. The company provides licorice products, including Gan Di Xin, an antitussive and expectorant medicine; Qilian Shan Licorice Extract, an ingredient for pharmaceutical companies to manufacture traditional licorice tablets; and Qilian Shan licorice liquid extract, a primary ingredient for medical preparation companies to produce compound licorice oral solutions. It offers Qilian Shan oxytetracycline tablets to prevent and treat a range of diseases in chickens, turkeys, cattle, swine, and human; and Qilian Shan oxytetracycline APIs for pharmaceutical companies to manufacture medications. In addition, the company offers TCMD products, such as Ahan antibacterial paste to treat refractory chronic skin diseases; heparin products, including heparin sodium preparations for pharmaceutical companies to produce medications for cardiovascular diseases, cerebrovascular diseases, and hemodialysis; and Zhu Xiaochang sausage casings, which are natural food products for culinary application. Further, it provides Xiongguan organic fertilizers to improve crop yield and soil's chemical properties and reduce soil compaction; and Xiongguan organic-inorganic compound fertilizers to increased plant growth. Qilian International Holding Group Limited was incorporated in 2019 and is based in Jiuquan, the People's Republic of China.
www.qlsyy.net298
Full Time Employees
September 30
Fiscal Year Ends
Sector
Recent News: QLI
Performance Overview: QLI
Trailing total returns as of 5/14/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: QLI
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: QLI
Valuation Measures
Market Cap
27.31M
Enterprise Value
5.47M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.59
Price/Book (mrq)
0.64
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-16.74%
Return on Assets (ttm)
-2.82%
Return on Equity (ttm)
-16.36%
Revenue (ttm)
46.47M
Net Income Avi to Common (ttm)
-7.78M
Diluted EPS (ttm)
-0.2200
Balance Sheet and Cash Flow
Total Cash (mrq)
22.42M
Total Debt/Equity (mrq)
1.30%
Levered Free Cash Flow (ttm)
-1.96M
Research Analysis: QLI
Company Insights: QLI
QLI does not have Company Insights